Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Ortisan Fruits & Fibre Cubes
010602000BBBCA0
|
Proprietary compound preparation BNF 0106020 | Other stimulant laxative preparations | Gastro-Intestinal System | 4 |
|
Sodium bicarbonate mixture paediatric
0101012B0AAALAL
|
Sodium bicarbonate (Antacids) | Sodium bicarbonate | Gastro-Intestinal System | 4 |
|
Sodium picosulfate 2.5mg capsules
0106020P0AAAFAF
|
Sodium picosulfate | Sodium picosulfate | Gastro-Intestinal System | 4 |
|
Fibrelief 3.5g granules sachets
0106010E0BLABAU
|
Fibrelief | Ispaghula husk | Gastro-Intestinal System | 3 |
|
Gaviscon Advance Mint chewable tablets (Forum Health)
0101021B0BEAYAP
|
Gaviscon | Alginic acid compound preparations | Gastro-Intestinal System | 3 |
|
Generic Rennie Deflatine chewable tablets sugar free
010102100AAABAB
|
Generic compound preparation BNF 0101021 | Compound alginates and proprietary indigestion preparations | Gastro-Intestinal System | 3 |
|
Germoloids HC spray
0107020J0BJAAAJ
|
Germoloids HC | Hydrocortisone | Gastro-Intestinal System | 3 |
|
Glycopyrronium bromide 1.5mg/5ml oral solution
0102000L0AABLBL
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | 3 |
|
Glycopyrronium bromide 2mg capsules
0102000L0AABKBK
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | 3 |
|
Glycopyrronium bromide 750micrograms/5ml oral liquid
0102000L0AAAFAF
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | 3 |
|
Hepa-Merz Granulat 3000 granules for oral solution sachets
0110010A0BBAAAA
|
Hepa-Merz Granulat | L-Ornithine-L-Aspartate | Gastro-Intestinal System | 3 |
|
Lofenoxal 2.5mg/25microgram tablets
0104020H0BGAAAA
|
Lofenoxal | Co-phenotrope (Diphenox hydrochloride/atropine sulfate) | Gastro-Intestinal System | 3 |
|
Mesalazine 250mg suppositories
0105010B0AAAGAG
|
Mesalazine | Mesalazine (Systemic) | Gastro-Intestinal System | 3 |
|
Pepto-Bismol 17.5mg/1ml oral suspension
010102100BBAWAG
|
Proprietary compound preparation BNF 0101021 | Compound alginates and proprietary indigestion preparations | Gastro-Intestinal System | 3 |
|
Phospho-soda 24.4g/10.8g oral solution
0106050U0BBAAAA
|
Phospho-soda | Phosphates | Gastro-Intestinal System | 3 |
|
S-Bicarb 420mg/5ml (1mmol/ml) oral solution
0101012B0BFAAAU
|
S-Bicarb | Sodium bicarbonate | Gastro-Intestinal System | 3 |
|
Ursodeoxycholic acid 300mg/5ml oral liquid
0109010U0AABHBH
|
Ursodeoxycholic acid | Ursodeoxycholic acid | Gastro-Intestinal System | 3 |
|
Atropine 600microgram tablets
0102000ACAAAGAG
|
Atropine sulfate (Oral) | Atropine sulfate | Gastro-Intestinal System | 2 |
|
Care Haemorrhoid Relief ointment
0107010N0BGAAAE
|
Care Haemorrhoid Relief | Lidocaine hydrochloride | Gastro-Intestinal System | 2 |
|
Co-danthrusate 50mg/60mg capsules
0106020J0AAAAAA
|
Co-danthrusate | Co-danthrusate (Dantron/docusate sodium) | Gastro-Intestinal System | 2 |
|
Crescent Pharma Liquid Laxative 5mg/5ml oral solution
0106020P0BFAAAB
|
Crescent Pharma | Sodium picosulfate | Gastro-Intestinal System | 2 |
|
Diarrhoea Relief 2mg capsules
0104020L0BSAAAA
|
Diarrhoea Relief | Loperamide hydrochloride | Gastro-Intestinal System | 2 |
|
Diltiazem 2% gel
0107010AAAAABAB
|
Diltiazem hydrochloride (Haemorrhoids) | Diltiazem hydrochloride | Gastro-Intestinal System | 2 |
|
Eluxadoline 100mg tablets
0102000AKAAAAAA
|
Eluxadoline | Eluxadoline | Gastro-Intestinal System | 2 |
|
Gaviscon Advance oral suspension aniseed (Forum Health)
0101021B0BEBAAL
|
Gaviscon | Alginic acid compound preparations | Gastro-Intestinal System | 2 |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.